Unlock instant, AI-driven research and patent intelligence for your innovation.

Bispecific binding agents binding to CD117/c-KIT and CD3

A bispecific, binding agent technology for anti-animal/human immunoglobulins, specific peptides, drug combinations, etc.

Pending Publication Date: 2022-06-21
UNIV ZURICH +1
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, so far, no such products have entered the market

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bispecific binding agents binding to CD117/c-KIT and CD3
  • Bispecific binding agents binding to CD117/c-KIT and CD3
  • Bispecific binding agents binding to CD117/c-KIT and CD3

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0170] According to one embodiment of the invention, the second binding domain that binds to CD3 comprises

[0171]a) the variable domain of an antibody selected from OKT3 and BlinCD3

[0172] b) Heavy chain / light chain variable domain (VD)

[0173] HC VD (SEQ ID NO 21 or 23), and

[0174] LC VD (SEQ ID NO 22 or 24)

[0175] c) the heavy chain / light chain variable domain (VD) of b), provided that

[0176] The HCVD has ≥80% sequence identity to the corresponding SEQ ID NO 21 or 23, and / or

[0177] LCDVD has >80% sequence identity to the corresponding SEQ ID NO 22 or 24.

[0178] d) the heavy chain / light chain variable domain (VD) of b), provided that at least one of HCVD or LCVD has at most 10 amino acid substitutions relative to the corresponding SEQ ID NO,

[0179] The bispecific binding agent is still capable of binding CD3.

[0180] Preferably, at least one variable domain has ≥81%, ≥82%, ≥83%, ≥84%, ≥85%, ≥86%, ≥87%, ≥88%, ≥89% with the corresponding SEQ ID NO %, ≥9...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to bispecific binding agents comprising at least a first binding domain and a second binding domain wherein the first binding domain binds CD117 / c-KIT and wherein the second binding domain binds CD3 (Fig. 1).

Description

technical field [0001] The present application relates to bispecific binding agents that bind CD117 / c-KIT and CD3. Background technique [0002] Bispecific antibodies, capable of redirecting T cell activity to target cells, represent a class of potent antibody products to achieve selective biocidal effects in vivo. In the presence of T cells, bispecific antibodies can kill target cells at subnanomolar concentrations [15]. A bispecific antibody product (blinatumomab) capable of simultaneously recognizing human CD19 and CD3 antigens has been approved for marketing for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) [16 ]. Blinatumomab is a bispecific T cell engager (BiTE TM ), a form of recombinant antibody produced by the sequential fusion of two single-chain Fv antibody fragments [17,18]. [0003] Self-renewing and immature hematopoietic stem and progenitor cells (HSCP) give rise to myeloid and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28C07K16/24C07K16/46A61P35/00
CPCC07K16/46C07K16/28A61P35/00C07K16/2809C07K16/2896C07K2317/31C07K2317/60C07K16/24C07K2317/76A61P35/02A61K2039/505C07K16/2803C07K2317/565C07K2317/567C07K2317/622C07K2317/92
Inventor J·基弗R·迈伯勒M·曼茨D·内里
Owner UNIV ZURICH